Norway-based medical diagnostics company Gentian Diagnostics AS (Euronext Growth Oslo:GENT) said on Friday that its SARS-CoV-2 antibody test is moving to the next development phase.
The project has progressed from the proof-of-concept phase to the project initiation and optimisation phase. Gentian has established an official project plan with an approved budget and a dedicated project team, and the timeline to launch is set for the fourth quarter of 2021.
Gentian's SARS-CoV-2 antibody test is designed to offer the first assay on high-throughput open-access clinical chemistry platforms, supporting COVID-19 vaccination efforts and aiding in community management by the determination of immunisation status.
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Hemogenyx Pharmaceuticals advances HG-CT-1 trial and opens paediatric recruitment
Rx to Go receives ACHC re-accreditation for pharmacy services
Shanton Pharma completes SAP-001 End-of-Phase 2 meeting with US FDA
Fibronostics completes Stone Clinical Laboratories acquisition
Syngene International to add GMP bioconjugation suite in Bengaluru
Eli Lilly's single-injection, once-monthly maintenance Omvoh regimen receives US FDA approval
4basebio synthetic DNA used in Phase I/II mRNA therapy trial